IRD · Opus Genetics, Inc. · Financials
Market Cap
$430.12M
Shares
83.20M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$14.2M
+29.1%
FY2025
Net Income
-$49.59M
+13.8%
FY2025
Operating Margin
-271.9%
+292.8pp
FY2025
Diluted EPS
-$0.80
+62.8%
FY2025
Operating Cash Flow
-$35.25M
-37.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 | FY2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $9.86M | $14.2M | $10.99M | $19.05M | $39.85M | $589K | $0 | $3M | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $100K | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$100K | — | — | — | — | — | — | — | |
| $38.62M | $30.81M | $26.85M | $17.65M | $14.36M | $15.17M | $6.65M | $5.48M | $13.11M | $10.72M | $10.09M | $12.15M | $7.02M | $3.25M | $3.39M | $11.99M | $3.93M | $3.18M | — | — | — | — | — | — | — | |
| $21.84M | $21.98M | $18.22M | $11.96M | $7.27M | $8.12M | $2.82M | $1.82M | $7.43M | $6.64M | $6.32M | $6.12M | $6.25M | $4.73M | $2.71M | $3.55M | $5.99M | $2.94M | — | — | — | — | — | — | — | |
| $36.55K | — | — | — | — | — | — | $40.99K | $48.21K | $42.36K | $32.92K | $27.5K | $28.33K | $37.13K | $42.39K | $45.07K | $50.66K | $41.6K | — | — | — | — | — | — | — | |
| $60.46M | $52.8M | $73.07M | $29.61M | $21.62M | $23.29M | $19.97M | $4.19M | $20.54M | $17.35M | $16.41M | $18.26M | $13.27M | $7.98M | $6.58M | $16.13M | $10.31M | $6.47M | — | — | — | — | — | — | — | |
| -$50.61M | -$38.6M | -$62.07M | -$10.56M | $18.23M | -$22.71M | -$19.97M | -$4.19M | -$20.54M | -$17.35M | -$16.41M | -$18.26M | -$13.27M | -$7.98M | -$6.58M | -$16.13M | -$10.31M | -$6.47M | — | — | — | — | — | — | — | |
| — | -271.9% | -564.72% | -55.45% | 45.74% | -3854.84% | — | -139.77% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$894.66K | — | — | — | — | — | — | -$4.15M | -$20.49M | -$17.31M | -$16.38M | -$18.24M | -$13.24M | -$7.94M | -$6.54M | -$16.09M | -$10.26M | -$6.42M | — | — | — | — | — | — | — | |
| $272K | $129K | $0 | $0 | $9000 | $2000 | $6.85M | $1.41M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $99.37K | — | — | — | — | — | — | $313.7K | $254.34K | $207K | $118.57K | $103.27K | $133.91K | $49.28K | $21.09K | $109.24K | $133.27K | $67.45K | — | — | — | — | — | — | — | |
| $3.74M | $1.99M | $4.47M | $1.84M | -$14K | -$157K | $9000 | $2.58M | $6.17M | -$7.94M | $7.11M | $3.88M | -$5.25M | -$1.52M | $352.86K | $4.79M | -$3.72M | $3.56M | — | — | — | — | — | — | — | |
| -$107.61M | -$49.59M | -$57.53M | -$9.97M | $18.2M | -$56.69M | -$24.62M | -$6.17M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $0 | $0 | $0 | $12K | $315K | $0 | $0 | $0 | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | |
| -$107.61M | -$49.59M | -$57.53M | -$9.99M | $17.89M | -$56.69M | -$24.62M | -$6.17M | -$14.37M | -$25.29M | -$9.31M | -$14.38M | -$18.52M | -$9.5M | -$6.23M | -$11.34M | -$14.02M | -$2.9M | -$3.68M | -$4.44M | -$6.49M | -$6.35M | -$3.27M | -$2.78M | -$1.18M | |
| — | -349.33% | -523.4% | -52.42% | 44.89% | -9625.3% | — | -205.63% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$107.61M | -$49.59M | -$57.53M | -$9.99M | $17.89M | -$56.69M | -$24.62M | -$6.17M | -$14.33M | -$25.35M | -$9.3M | -$14.37M | -$18.56M | -$9.5M | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | -$1.27 | -$0.80 | -$2.15 | -$0.46 | $0.90 | -$3.82 | -$5.28 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$1.33 | -$0.80 | -$2.15 | -$0.46 | $0.87 | -$3.82 | -$5.28 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 62.22M | 26.72M | 21.59M | 19.93M | 14.85M | 4.66M | 2.84M | 684.63K | 6.85M | 5.44M | 4.56M | 44.03M | 32.16M | 24.28M | 23.26M | — | — | — | — | — | — | — | — | — |
| shares | — | 62.22M | 26.72M | 21.59M | 20.6M | 14.85M | 4.66M | 2.84M | 684.63K | 6.85M | 5.44M | 4.56M | 44.03M | 32.16M | 24.28M | 23.26M | — | — | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2011: $0 in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
38.21×
Peer median 5.40×
EV/EBIT
—
Peer median 9.04×
P/E (TTM)
—
Peer median 12.30×
Peer medians compare against the 314 similar-size Biotechnology companies (of 534 listed).